Yahoo Finance will chronicle the latest news and updates on Trump's tariffs — from the threats to the eventual policy.

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

Gorilla Technology Group Inc. (NASDAQ: GRRR) ("Gorilla" or the "Company") is pleased to invite investors to a webinar on ...